Holen Sie sich die Stockscreener-App
32.94
3.29%
-1.12
Vorhandelsmarkt:
32.84
-0.10
-0.30%
Schlusskurs vom Vortag:
$34.06
Offen:
$34.09
24-Stunden-Volumen:
412.83K
Relative Volume:
0.39
Marktkapitalisierung:
$2.06B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-230.66M
KGV:
-7.8913
EPS:
-4.1742
Netto-Cashflow:
$-148.12M
1W Leistung:
+6.05%
1M Leistung:
-11.02%
6M Leistung:
+36.51%
1J Leistung:
+780.75%
1-Tages-Spanne:
$32.55
$34.48
1-Wochen-Bereich:
$30.26
$35.51
52-Wochen-Spanne:
$3.43
$47.84
Kodiak Sciences Inc Stock (KOD) Company Profile
Firmenname
Kodiak Sciences Inc
Sektor
Branche
Telefon
650-281-0850
Adresse
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
32.94 | 2.13B | 0 | -230.66M | -148.12M | -4.1742 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-25 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-09-22 | Eingeleitet | Jefferies | Buy |
| 2025-08-14 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2023-12-11 | Fortgesetzt | Goldman | Sell |
| 2023-11-17 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-25 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-15 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2022-02-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-11-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-03 | Eingeleitet | Goldman | Buy |
| 2020-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Eingeleitet | SunTrust | Buy |
| 2020-01-08 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-03 | Eingeleitet | Jefferies | Buy |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2018-10-29 | Eingeleitet | Barclays | Overweight |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Buy |
| 2018-10-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences (KOD) Edges Higher: Biotech Momentum Builds at $34.55ATR Stop - newsline.com
Kodiak stock rises 35% in 3 months: Here's what you need to know - MSN
Kodiak Sciences Inc. - MLQ.ai
Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus - Sahm
Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans - Yahoo Finance
Kodiak Sciences CFO John Borgeson sold $1.02 million in NASDAQ:KOD shares By Investing.com - Investing.com South Africa
Kodiak Sciences CFO John Borgeson sold $1.02 million in NASDAQ:KOD shares - Investing.com Nigeria
Kodiak (KOD) CFO sells 30,000 shares under 10b5-1 trading plan - Stock Titan
Why Did KOD Stock Surge To A Four-Year High Today? - Stocktwits
Kodiak Sciences Inc. (KOD) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Kodiak Sciences Inc. Files Form 8-K with SEC Detailing Company and Stock Information (June 2026) - Minichart
Kodiak Sciences Stockholders Back Directors and Governance Proposals - TipRanks
Kodiak Sciences (NASDAQ: KOD) 2026 meeting approves all proposals - Stock Titan
KOD (NASDAQ: KOD) scheduled sale of 30,000 shares after option exercise - Stock Titan
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know - The Globe and Mail
Kodiak Sciences CEO to present at 2026 Jefferies Global Healthcare Conference on June 4 - Pluang
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference - 富途牛牛
Kodiak Sciences CEO to speak at 2026 Jefferies healthcare event - Stock Titan
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally - AOL.com
Kodiak Sciences Falls Before Holiday Pause With Eyes on Drug Update - Bez Kabli
KOD Technical Analysis | Trend, Signals & Chart Patterns | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences Inc stock (US50012K1051): earnings loss widens as biotech pushes retina pipeline - AD HOC NEWS
Kodiak Sciences Inc stock (US50012K1051): what’s behind the latest volatility after eye disease se - AD HOC NEWS
Boxer Capital Management Boosts Kodiak Sciences Holdings in Q1 2026News and Statistics - IndexBox
Kodiak Sciences Inc stock (US50012K1051): Investors eye eye-disease pipeline after latest company up - AD HOC NEWS
Kodiak Sciences stock hits 52-week highhere's why - MSN
Kodiak Sciences (KOD) price target increased by 16.91% to 66.30 - MSN
Sirenia Capital (KOD) and Alex Silverstein report 3,495,000 shares (5.7%) - Stock Titan
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
Kodiak Sciences stock (US50012K1051): Q4 2025 earnings miss sparks investor focus - AD HOC NEWS
Kodiak Sciences (KOD) up 2% since last earnings report: Can it continue? - MSN
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Cuts Target Price to $56 - Moomoo
Number of shareholders of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD), IN8bio (INAB) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Chardan Capital upgrades Kodiak Sciences (KOD) - MSN
TradingKey - TradingKey
KOD Upgraded by Chardan Capital -- Price Target Raised to $61.00 - GuruFocus
This Pitney Bowes Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
Chardan upgrades Kodiak Sciences stock rating on drug trial results By Investing.com - Investing.com South Africa
Chardan upgrades Kodiak Sciences stock rating on drug trial results - Investing.com
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Kodiak's Q1 loss wider than expected, pipeline development in focus - MSN
A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda - Yahoo Finance
Zenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD) - Yahoo Finance
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Finanzdaten der Kodiak Sciences Inc-Aktie (KOD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kodiak Sciences Inc-Aktie (KOD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Sale |
34.10 |
30,000 |
1,023,009 |
211,930 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):